Rapport Therapeutics, Inc. Common Stock (RAPP) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-96.8%

$0.79

vs $25.13 price

Levered DCF

$0.88

After debt service

Piotroski score

2 / 9

Weak

Altman Z-score

19.18

Safe zone

Rating

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022
P/E	-10.61×	-4.69×	-21.89×	-71.72×
P/B	2.94×	1.2×	-14.67×	21.45×
P/S	0×	0×	0×	0×
EV / EBITDA	-11.16×	-3.8×	-8.54×	-38.42×
Gross margin	0.0%	0.0%	0.0%	0.0%
Operating margin	0.0%	0.0%	0.0%	0.0%
Net margin	0.0%	0.0%	0.0%	0.0%
Current ratio	26.17×	35.34×	17.14×	18.8×
Debt / equity	0.02×	0×	-0.08×	0.53×
Interest coverage	0×	0×	0×	-36.38×
Dividend yield	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022
Return on equity	-23.0%	-25.6%	135.7%	-54.6%
Return on invested capital	-25.2%	-27.1%	-24.6%	-34.6%
Return on assets	-21.8%	-24.9%	-22.4%	-33.7%
Free cash flow yield	-6.2%	-18.3%	-7.7%	-0.8%
Earnings yield	-7.8%	-21.3%	-9.3%	-2.5%
Enterprise value	$1.4B	$312.6M	$308M	$397.7M
Net debt / EBITDA	0.33×	0.67×	1.89×	2×
Cash conversion cycle (days)	0	0	0	-35,283